التفاصيل البيبلوغرافية
| العنوان: |
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial. |
| المؤلفون: |
McCreary, Erin K.1 (AUTHOR), Bariola, J. Ryan1 (AUTHOR), Minnier, Tami E.2 (AUTHOR), Wadas, Richard J.3 (AUTHOR), Shovel, Judith A.2 (AUTHOR), Albin, Debbie4 (AUTHOR), Marroquin, Oscar C.5 (AUTHOR), Kip, Kevin E.5 (AUTHOR), Collins, Kevin5 (AUTHOR), Schmidhofer, Mark6 (AUTHOR), Wisniewski, Mary Kay2 (AUTHOR), Nace, David A.7 (AUTHOR), Sullivan, Colleen8,9 (AUTHOR), Axe, Meredith3 (AUTHOR), Meyers, Russell3 (AUTHOR), Weissman, Alexandra3 (AUTHOR), Garrard, William5 (AUTHOR), Peck-Palmer, Octavia M.10 (AUTHOR), Wells, Alan10 (AUTHOR), Bart, Robert D.11,12 (AUTHOR) |
| المصدر: |
Contemporary Clinical Trials. Aug2022, Vol. 119, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*COVID-19, *CLINICAL trials, *BAYESIAN analysis, *INSTRUCTIONAL systems, *ODDS ratio, *MONOCLONAL antibodies |
| مستخلص: |
Monoclonal antibodies (mAb) that neutralize SARS-CoV-2 decrease hospitalization and death compared to placebo in patients with mild to moderate COVID-19; however, comparative effectiveness is unknown. We report the comparative effectiveness of bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab. A learning health system platform trial in a U.S. health system enrolled patients meeting mAb Emergency Use Authorization criteria. An electronic health record-embedded application linked local mAb inventory to patient encounters and provided random mAb allocation. Primary outcome was hospital-free days to day 28. Primary analysis was a Bayesian model adjusting for treatment location, age, sex, and time. Inferiority was defined as 99% posterior probability of an odds ratio < 1. Equivalence was defined as 95% posterior probability the odds ratio is within a given bound. Between March 10 and June 25, 2021, 1935 patients received treatment. Median hospital-free days were 28 (IQR 28, 28) for each mAb. Mortality was 0.8% (1/128), 0.8% (7/885), and 0.7% (6/922) for bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab, respectively. Relative to casirivimab-imdevimab (n = 922), median adjusted odds ratios were 0.58 (95% credible interval [CI] 0.30–1.16) and 0.94 (95% CI 0.72–1.24) for bamlanivimab (n = 128) and bamlanivimab-etesevimab (n = 885), respectively. These odds ratios yielded 91% and 94% probabilities of inferiority of bamlanivimab versus bamlanivimab-etesevimab and casirivimab-imdevimab, and an 86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab. Among patients with mild to moderate COVID-19, bamlanivimab-etesevimab or casirivimab-imdevimab treatment resulted in 86% probability of equivalence. No treatment met prespecified criteria for statistical equivalence. Median hospital-free days to day 28 were 28 (IQR 28, 28) for each mAb. This work received no external funding. The U.S. government provided the reported mAb. This trial is registered at ClinicalTrials.gov , NCT04790786. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
